Showing results (251-260 of 4,238) with videos related to
Sort By:
Pageof 424
Journal for Immunotherapy of Cancer|April 2, 2021
New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor modelsAlessandra Lopes, Chiara Bastiancich, Mathilde Bausart, et al.Journal for Immunotherapy of Cancer|April 2, 2021
Current strategies to circumvent the antiviral immunity to optimize cancer virotherapyDong Ho Shin, Teresa Nguyen, Bulent Ozpolat, et al.Journal for Immunotherapy of Cancer|April 2, 2021
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trialsZi-Xian Wang, Hao-Xiang Wu, Li Xie, et al.Journal for Immunotherapy of Cancer|April 12, 2023
Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosisAna Belen Moreno-Castaño, Sara Fernández, Helena Ventosa, et al.Journal for Immunotherapy of Cancer|April 7, 2023
Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanomaLuiza Martins Nascentes Melo, Dayana Herrera-Rios, Daniel Hinze, et al.Journal for Immunotherapy of Cancer|July 29, 2020
Checkpoint inhibitor-related renal vasculitis and use of rituximabOmar Mamlouk, Jamie S Lin, Maen Abdelrahim, et al.Journal for Immunotherapy of Cancer|July 31, 2020
SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunityJia Wei, Jianping Zhao, Meifang Han, et al.Journal for Immunotherapy of Cancer|February 24, 2015
Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndromeBenjamin P Geisler, Roy A Raad, Diana Esaian, et al.Journal for Immunotherapy of Cancer|August 22, 2020
M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancerMichal Hensler, Lenka Kasikova, Karel Fiser, et al.Journal for Immunotherapy of Cancer|May 23, 2023
Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case reportDarien E Reed-Perino, Michael Lai, Evan Y Yu, et al.Pageof 424